Blog of Signaling Pathways

EPZ5676 is an Sadenosyl methionine competitive inhibitor

1961 views | Dec 24 2013

EPZ-5676 reduces H3K79 dimethylation with a cellular IC50 of 2.6 nM in MV4-11 cells. [Read the Full Post]

Brefeldin A used to enhance intracellular cytokine staining signals

2609 views | Dec 23 2013

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. [Read the Full Post]

SB939 is a novel histone deacetylas inhibitor with improved

3665 views | Dec 23 2013

SB939 is a potent pan-HDAC inhibitor with IC50 of 40-140 nM with exception for HDAC6. It has no activity against the class III isoenzyme SIRT I. [Read the Full Post]

Dasatinib is a cancer drug produced by Bristol Myers Squibb

3394 views | Dec 23 2013

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively. [Read the Full Post]

ABT 737 is a small molecule that acts as a selective inhibitor of Bcl 2

2604 views | Dec 23 2013

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. [Read the Full Post]

ABT 888 is a potential anti cancer drug acting as a PARP inhibitor

4076 views | Dec 20 2013

ABT-888 is inactive to SIRT2 (>5 μM) .ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells. [Read the Full Post]

Dapagliflozin is a drug used to treat type 2 diabetes

0 views | Dec 20 2013

Dapagliflozin is 32-fold more potent than phlorizin against hSGLT2 but 4-fold less than phlorizin against hSGLT1. [Read the Full Post]

Deforolimus is a small molecule inhibitor of the mammalian target of rapamycin

2117 views | Dec 19 2013

Ridaforolimus is a selective mTOR inhibitor with IC50 of 0.2 nM; while not classified as a prodrug, mTOR inhibition and FKBP12 binding is similar to rapamycin. [Read the Full Post]

Wnt C59 was first disclosed in patent WO2010101849 as a potent

3606 views | Dec 19 2013

Wnt-C59 is claimed to inhibit PORCN enzyme activity at nanomolar concentrations. [Read the Full Post]

Tipifarnib is a farnesyltransferase inhibitor

2353 views | Dec 18 2013

Tipifarnib (R115777) is a potent and specific farnesyltransferase (FTase) inhibitor with IC50 of 0.6 nM, its anti-proliferative effects are most prominent in H-ras or N-ras mutant cells. [Read the Full Post]

AZD0530 is a dually active inhibitor of c Src and Bcr ABL

2849 views | Dec 18 2013

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). [Read the Full Post]

Givinostat is a histone deacetylase inhibitor with potential

3342 views | Dec 17 2013

Givinostat (ITF2357) is a potent HDAC inhibitor for HDAC2, HDAC1B and HDAC1A with IC50 of 10 nM, 7.5 nM and 16 nM. [Read the Full Post]

Abt199 is designed to block the function of the protein Bcl 2

2200 views | Dec 17 2013

ABT-199 (GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. [Read the Full Post]

Bortezomib is the first clinically approved proteasome inhibitor for treating multiple human malignancies

2897 views | Dec 16 2013

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. [Read the Full Post]

LY335979 is a potent inhibitor that contains a cyclopropyldibenzosuberane moiety

3893 views | Dec 16 2013

LY335979 competitively inhibits equilibrium binding of vinblastine to Pgp by blocking azidopine photoaffinity labeling of the Pgp in CEM/VLB100 plasma membranes. [Read the Full Post]

AT101 was developed to put requirements in place for CPAs

2320 views | Dec 13 2013

AT-101 inhibits a panel of different lymphoproliferative malignancies with IC50 ranged from 1.2 μM to 7.4 μM. [Read the Full Post]

Pki587 is a highly potent dual PI3K kinase inhibitor

2170 views | Dec 13 2013

PKI-587 shows potent inhibitory activity against PI3K-α, PI3K-γ and mTOR with IC50 of 0.4 nM, 5.4 nM and 1.6 nM, respectively. [Read the Full Post]

Olaparib is an experimental chemotherapeutic agent

0 views | Dec 12 2013

Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. [Read the Full Post]

OSI 930 is a novel inhibitor of the receptor tyrosine kinases Kit and kinase

2202 views | Dec 12 2013

OSI-930 inhibits the cell proliferation in the HMC-1 cell line with IC50 of 14 nM without significant effect on growth of the COLO-205 cell line that does not express a constitutively active mutant receptor tyrosine kinase. [Read the Full Post]

XAV 939 is a small molecule and selective Wnt pathway

3877 views | Dec 11 2013

XAV-939 specifically inhibits tankyrase PARP activity. [Read the Full Post]